Methotrexate (Post-conception)

Study Reference
Cooper (Controls exposed to other treatment, sick), 2014

Cooper Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy. 2014; 66:444-50

Cooper (Controls unexposed, sick), 2014

Cooper Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy. 2014; 66:444-50

Dawson, 2014

Dawson Maternal exposure to methotrexate and birth defects: a population-based study. Am J Med Genet A 2014; 164A:2212-6

Howren, 2020

Howren Perinatal exposure to conventional synthetic disease-modifying anti-rheumatic drugs in women with rheumatic disease and neonatal outcomes: a population-based study. Clin Exp Rheumatol ; 38:1080-1087

Viktil (Controls exposed to other treatment, sick), 2012

Viktil Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012; 41:196-201

Viktil (Controls unexposed NOS), 2012

Viktil Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012; 41:196-201

Vinet, 2013

Vinet Induced abortions in women with rheumatoid arthritis receiving methotrexate. Arthritis Care Res (Hoboken) 2013; 65:1365-9

Weber-Schoendorfer (Controls exposed to other treatment, sick), 2014

Weber-Schoendorfer Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol 2014; 66:1101-10

Weber-Schoendorfer (Controls unexposed, disease free), 2014

Weber-Schoendorfer Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol 2014; 66:1101-10